The latest biotech news

News and Trends 8 Sep 2022

Cultivated Biosciences raises $1.5M to take fats to the next frontier

Cultivated Biosciences, an ingredient startup biotech company founded by Swiss entrepreneurs Tomas Turner and Dimitri Zogg, has just raised a $1.5M pre-seed round. The funding will enable the growing team to further optimize its production processes, research food applications and start product development of its creamy ingredient for dairy alternatives from non-GMO yeast with their […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

More News! 7 Sep 2022

Powerful, organic turmeric produced by controlled fermentation process

A controlled fermentation process has been used to produce an organic turmeric – a natural herb known for its health benefits and organoleptic properties. German pharmaceutical company, Cellavent, has recently entered the fermented botanical space with product, fermentlife Turmeric. Cellavent says its product is a powerful new organic turmeric that can offer a wide range […]

September 7, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Sep 2022

Oncopeptides receives grant for NK-cell engager project in multiple myeloma

Oncopeptides AB has received a SEK 5 million ($465,000) research grant from Sweden’s Innovation Agency. The Swedish biotech company, which focuses on R&D of therapies for difficult-to-treat hematological diseases, will use the funds to develop a preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Lesaffre acquires genome editing company Recombia Biosciences

Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Adocia takes steps with implants for treatment of type 1 diabetes

French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during a 132-day study. AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, has announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab). The supply agreement with Regeneron will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Benchling launches solution to boost mRNA and RNA therapeutics development

Benchling has launched what it says is the industry’s first full set of capabilities for designing, modeling, and studying natural and chemically modified RNA in a single solution. As the biopharma industry increases its focus on developing RNA therapeutics, Benchling said its new RNA solution is the first purpose-built offering on the market to help […]

September 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Alzinova announces new positive safety review for Alzheimer’s study

Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Lytix Biopharma expanding advanced melanoma study to Europe

Lytix Biopharma, a Norwegian immuno-oncology company, has received regulatory approval from European authorities to start its ATLAS-IT-05 study in three European countries. ATLAS-IT-05 is a phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Ionis presents positive study results at International Symposium on amyloidosis

Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Could COVID vaccine boosters become obsolete?

A team of researchers at Tel Aviv University in Israel has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus, including the Delta and the Omicron variants. According to the researchers, this discovery may eliminate the need for repeated booster vaccinations and […]

September 7, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Cultivated Biosciences raises $1.5M to take fats to the next frontier

Powerful, organic turmeric produced by controlled fermentation process

Oncopeptides receives grant for NK-cell engager project in multiple myeloma

Lesaffre acquires genome editing company Recombia Biosciences

Adocia takes steps with implants for treatment of type 1 diabetes

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

Benchling launches solution to boost mRNA and RNA therapeutics development

Alzinova announces new positive safety review for Alzheimer’s study

Lytix Biopharma expanding advanced melanoma study to Europe

Ionis presents positive study results at International Symposium on amyloidosis

Could COVID vaccine boosters become obsolete?

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!